ReviewMaterials today. Bio2025
Engineered anti-cancer nanomedicine for synergistic cuproptosis-immunotherapy.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Recent progress in cGAS-STING agonist design and mechanisms of cancer immune modulation.RSC chemical biology · 2026Review
- Reprogramming temozolomide response in glioblastoma through regulated and immunogenic cell death modalities.Cell death discovery · 2026Review
- Review
- Nanomedicine in immunotherapy of urinary system tumors: advances, synergistic strategies, and translational challenges.Journal of nanobiotechnology · 2026Review
- Metal-based nanodrugs for cancer immunotherapy: smart nanosystems, immunomodulatory mechanisms, and translational perspectives.Frontiers in chemistry · 2026Review
- Cuproptosis and anti-tumor immunity: bidirectional regulation, controversies, and translational prospects.Frontiers in immunology · 2026Review
- Cu-doped dendritic biodegradable nanoplatforms for augmenting cuproptosis and tumor-starvation therapy through mitochondrial metabolic cascade modulation.Materials today. Bio · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor immunotherapy has seen remarkable progress in recent cancer treatments. However, its broad clinical application is hindered by several challenges, such as the low immunogenicity of "cold tumors," immunosuppressive conditions within the tumor microenvironment, and persistent immune evasion of cancer cells. Therefore, selectively enhancing the immune response during cancer therapy is crucial. Cuproptosis is a newly identified form of regulated cell death that is characterized by the accumulation of intracellular copper ions, leading to lipoylated protein aggregation and subsequent metabolic dysfunction. This process is intricately linked with the tumor microenvironment. By activating targeted mechanisms, cuproptosis can selectively trigger immune responses within tumor regions, thereby addressing the issue of tumor-mediated immune evasion. Cuproptosis holds promise for improving the efficacy of immunotherapy by promoting a more robust anti-tumor immune response within the tumor microenvironment. The combination of cuproptosis-inducing strategies with immunotherapeutic approaches presents a novel and potentially effective direction for future cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.